Gilead Sciences stock at EUR 148.79, down 2.18% premarket
Published on 11/04/2026 at 08:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points for investors
- Gilead lifted its 2026 product-sales outlook after third-quarter product sales rose 13%.
- HIV sales increased 18%, while Veklury sales fell 69% year over year.
- Management scheduled further investor presentations for November and December.
Gilead Sciences stock traded at 148.79 euros on Lang & Schwarz at 08:02 CET on Wednesday, November 4, 2026, 2.18 percent below the Xetra close of Tuesday, November 3, at 152.10 euros.
See the real-time quote of Gilead Sciences stock for the latest trading price.
Growth meets a heavier outlook
In its third-quarter results release dated October 29, Gilead Sciences said product sales rose 13 percent year over year to USD 8.3 billion. Product sales excluding Veklury increased 16 percent to USD 8.2 billion, while total revenue grew 7 percent to USD 8.3 billion.
The company raised its 2026 product-sales outlook to USD 31.0 billion to USD 31.3 billion from USD 30.1 billion to USD 30.4 billion previously. The outlook for product sales excluding Veklury rose to USD 30.7 billion to USD 31.0 billion. Gilead also expects a GAAP diluted loss of USD 4.40 to USD 4.05 per share, reflecting major acquired in-process research and development charges.
HIV strength offsets pressure elsewhere
HIV product sales rose 18 percent to USD 6.2 billion, led by Biktarvy sales up 10 percent to USD 4.1 billion and Descovy sales up 49 percent to USD 1.0 billion. Trodelvy sales increased 42 percent to USD 506 million, while Veklury sales dropped 69 percent to USD 86 million and Cell Therapy sales fell 18 percent to USD 355 million.
GAAP diluted earnings per share declined to USD 1.94 from USD 2.43 a year earlier, while non-GAAP diluted earnings per share rose to USD 2.55 from USD 2.47. Investors will next focus on Gilead's scheduled healthcare conferences beginning with the Wolfe Research Healthcare Conference on November 10.
US-listed shares are followed in the broader market context of the S&P 500.
More news and analyses on Gilead Sciences stock provide further coverage of the company and its pipeline.
